Latest Breaking News On - Hunter hopkins center - Page 3 : comparemela.com

AIM ImmunoTech (AIM) Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

AIM ImmunoTech (AIM) Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel petersonThomask equelsCharles lappHunter hopkins centerImmunotech incAccess programExpanded access programSierra internal medicineIncline villageFatigue overPost acute sequelaeChronic fatigue syndrome

AIM ImmunoTech Reports Positive Pilot Study Data from

AIM ImmunoTech Reports Positive Pilot Study Data from
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel petersonThomask equelsCharles lappHunter hopkins centerImmunotech incAccess programExpanded access programSierra internal medicineIncline villageFatigue over

AIM ImmunoTech Inc to file Investigational New Drug application for Ampligen to treat long COVID

AIM ImmunoTech Inc (NYSE:AIM) has announced that it is working towards filing an Investigational New Drug (IND) application with the US Food and Drug.

United statesCharlotte charles lappDavid strayerHunter hopkins centerImmunotech incDrug administrationTech incInvestigational new drug

AIM ImmunoTech (AIM) Provides Update on Ampligen Long COVID Development Program

AIM ImmunoTech (AIM) Provides Update on Ampligen Long COVID Development Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDavid strayerThomask equelsCharles lappHunter hopkins centerUs centers for diseaseImmunotech incDrug administrationWall streetDisease controlPatient reported outcomesInvestigational new drugMedical officer david strayerPrincipal investigatorPost acute sequelaeLong haulers

AIM ImmunoTech to Participate in a Solve M E Diagnostics

AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm - 3:00 pm ET Company to discuss clinical plans for investigational.

United statesDavidr strayerGunnar gottschalkJenene thomasThomask equelsCharles lappHunter hopkins centerImmunotech incSimmaron research incInitiative solveTreatments webinarGeneral overviewChief executive officerChief scientificMedical officerSolve president